ATX-GD-59 (1.6mg)

Introducing ATX-GD-59, a cutting-edge peptide-based therapy meticulously crafted for the management of Graves’ disease. With a molecular weight of 2529.26 and a molecular formula of C114H198N32O32, ATX-GD-59 surpasses research-grade benchmarks, highlighting our unwavering dedication to excellence and pioneering advancements.

ATX-GD-59 redefines medical paradigms through its innovative mode of action, engineered to emulate epitopes and effectively immobilize the leukocytes responsible for assaulting the thyroid. It obstructs the generation of anti-thyroid stimulating hormone receptor (TSHR) stimulatory antibodies, revolutionizing the approach beyond conventional treatments. This advanced strategy homes in on the immunological foundation of Graves’ disease, marking a transformative path in disease management brought forth by ATX-GD-59.